Aclaris Therapeutics And 2 Other US Penny Stocks To Watch

In This Article:

As the United States market continues its upward trend, with the S&P 500 extending its winning streak and Bitcoin reaching record highs, investors are looking for opportunities beyond the well-known giants. Penny stocks, often representing smaller or newer companies, remain a relevant investment area despite their somewhat outdated name. These stocks can offer surprising value and stability when backed by solid financial foundations.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.8368

$5.81M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$143.63M

★★★★★★

So-Young International (NasdaqGM:SY)

$1.25

$84.67M

★★★★☆☆

Better Choice (NYSEAM:BTTR)

$1.7017

$3.25M

★★★★★★

Puma Biotechnology (NasdaqGS:PBYI)

$2.90

$139.41M

★★★★★★

RLX Technology (NYSE:RLX)

$1.78

$2.31B

★★★★★★

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8694

$76.61M

★★★★★☆

PHX Minerals (NYSE:PHX)

$3.74

$138.68M

★★★★★☆

Click here to see the full list of 740 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Aclaris Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune-inflammatory diseases in the United States, with a market cap of $282.87 million.

Operations: The company's revenue is derived from two main segments: Therapeutics, generating $24.59 million, and Contract Research, contributing $17.04 million.

Market Cap: $282.87M

Aclaris Therapeutics, Inc. has recently secured an exclusive license agreement with Biosion, Inc. for promising antibody therapies, potentially enhancing its pipeline in immune-inflammatory diseases. Despite being unprofitable with declining revenues of US$4.35 million in the latest quarter, Aclaris has significantly reduced its net loss and maintains a solid cash position with no debt and assets covering liabilities comfortably. The company bolstered its leadership team with experienced hires from major pharmaceutical firms, which may support future strategic initiatives. However, high share price volatility and projected earnings decline remain concerns for investors considering this penny stock.

NasdaqGS:ACRS Debt to Equity History and Analysis as at Nov 2024
NasdaqGS:ACRS Debt to Equity History and Analysis as at Nov 2024

Allot

Simply Wall St Financial Health Rating: ★★★★☆☆